Cellect Biotechnology Ltd. Warrants to Purchase ADRs
APOPW
APOPW was delisted on the 3rd of August, 2021.
2 hedge funds and large institutions have $373K invested in Cellect Biotechnology Ltd. Warrants to Purchase ADRs in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$83.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$35.9K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AFM
1
Anson Funds Management
Dallas,
Texas
| $350K | +$83.9K | +113,347 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $23K | +$35.9K | +48,515 | New |
|
APOPW Hedge Fund Activity: Q4 2016 in Review
2 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) for Q4 2016, worth a combined $373K.
Buyers outnumbered sellers: 2 funds opened new APOPW positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $83.9K.
- 2 institutional investors held Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) as of Q4 2016, up from 0 in Q3 2016.
- Funds reported $373K of Cellect Biotechnology Ltd. Warrants to Purchase ADRs stock for Q4 2016.
- 2 funds opened new Cellect Biotechnology Ltd. Warrants to Purchase ADRs positions in Q4 2016 and 0 closed out, a net change of +2 holders.
- The largest Cellect Biotechnology Ltd. Warrants to Purchase ADRs buyer in Q4 2016 was Anson Funds Management, an estimated $83.9K added.
Based on aggregated 13F filings for Q4 2016.